DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,020.00
-70.00 (-1.38%)
At close: Aug 7, 2025, 3:30 PM KST
-1.38%
Market Cap137.10B
Revenue (ttm)243.74B
Net Income (ttm)-3.04B
Shares Out27.04M
EPS (ttm)-111.93
PE Ration/a
Forward PEn/a
Dividend120.00 (2.39%)
Ex-Dividend DateDec 27, 2024
Volume49,772
Average Volume48,564
Open5,120.00
Previous Close5,090.00
Day's Range5,000.00 - 5,120.00
52-Week Range4,300.00 - 7,290.00
Beta0.62
RSI45.62
Earnings DateAug 11, 2025

About DongKoo Bio & Pharma

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antip... [Read more]

Industry Pharmaceutical Preparations
Founded 1970
Employees 393
Stock Exchange KOSDAQ
Ticker Symbol 006620
Full Company Profile

Financial Performance

In 2024, DongKoo Bio & Pharma's revenue was 249.27 billion, an increase of 15.57% compared to the previous year's 215.69 billion. Earnings were 2.04 billion, a decrease of -82.77%.

Financial Statements

News

There is no news available yet.